Drugs / Garsorasib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07472478 | Mar 2026 → Dec 2027 expected | non-small cell lung carcinoma | Guangdong Provincial People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07294261 | Dec 2025 → Oct 2028 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07601048 Comparator | Jun 2026 → May 2028 expected | — | Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-06-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Results 喜讯！格索雷塞治疗晚期或转移性结直肠癌研究结果荣登国际权威期刊STTT cttq.com ↗
结果表明[1]，格索雷塞单药或联合西妥昔单抗治疗晚期或转移性CRC均显示出良好的抗肿瘤活性。 |
| 2024-12-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Results 2024新药成绩单，正大天晴领跑肿瘤1类创新药赛道 cttq.com ↗ |
| 2024-11-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Regulatory 正大天晴今年第四款1类创新药！KRAS G12C靶向药格索雷塞获批上市 cttq.com ↗
11月8日，国家药监局官网显示，正大天晴联合开发的KRAS G12C抑制剂格索雷塞片（商品名：安方宁）获批准上市，适用于治疗至少接受过一种系统性治疗的鼠类肉瘤病毒癌基因（KRAS）G12C 突变型的晚期非小细胞肺癌（NSCLC）成人患者。 |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 喜讯！格索雷塞治疗晚期或转移性结直肠癌研究结果荣登国际权威期刊STTT cttq.com ↗ |
| 2024-12-23 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024新药成绩单，正大天晴领跑肿瘤1类创新药赛道 cttq.com ↗ |
| 2024-11-11 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 正大天晴今年第四款1类创新药！KRAS G12C靶向药格索雷塞获批上市 cttq.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Garsorasib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07601048 ↗ |